TB tests are available at most primary care clinics, urgent care centers, local health departments, pharmacies with walk-in clinics, and occupational health offices. Many employers, schools, and immigration processes require TB testing, so access points tend to be widespread in most developed countries. The test itself comes in two forms, a skin injection or a blood draw, and each involves a different timeline and procedure. Understanding which test fits your situation and what the results mean can save you a second trip and some unnecessary worry.
The Two Main Types of TB Tests
There are two categories of TB test in common use, and the location you visit will typically offer one or both. The first is the tuberculin skin test, often called the Mantoux test or TST. This is the classic forearm injection that has been used in various forms since the early twentieth century, originally developed from Koch’s tuberculin solution and later refined into the purified protein derivative still used today.1PubMed Central. Latent tuberculosis testing through the ages: the search for a sleeping killer The second is a blood test known as an interferon-gamma release assay, or IGRA. Two commercial IGRAs are widely available: QuantiFERON-TB Gold Plus and T-SPOT.TB. Both work by measuring how your immune cells respond to proteins specific to the TB bacterium.
The skin test requires two visits. The blood test requires one. That single practical difference drives a lot of the decision-making about which test gets used where.
What Happens During a Skin Test
For the TST, a healthcare worker injects a tiny amount of purified protein derivative just under the skin of your inner forearm. It is an intradermal injection, meaning the needle goes into the top layers of skin rather than into muscle or a vein. A small, pale bump called a wheal forms at the injection site. The injection itself is quick and causes only a brief sting.
Here is the part that surprises people: you cannot read the result that day. You must return to the clinic 48 to 72 hours later so a trained reader can measure the reaction. What they are looking for is induration, which is a firm, raised area of skin at the injection site. Redness alone does not count. The reader runs a finger across the spot to feel for hardness and then measures the diameter of the raised area in millimeters. If you miss the reading window, the test is invalid and you have to start over.
The measurement thresholds vary depending on your risk profile. For people with weakened immune systems or known close contact with an active TB case, a bump of 5 millimeters or more is considered positive. For people with no major risk factors but who were vaccinated with BCG as children, the threshold may be set at 15 millimeters to reduce false positives.2The Lancet Infectious Diseases. Diagnostic performance of new skin tests and purity protein derivative-tuberculin skin test for tuberculosis infection: a systematic review and meta-analysis Most otherwise healthy adults in the United States fall under a 10-millimeter cutoff. Your provider decides which threshold applies to you based on your medical history and exposure risk.
What Happens During a Blood Test
If your provider orders an IGRA instead, the experience is simpler from your end. A phlebotomist draws a standard blood sample, usually from a vein in your arm, and the blood gets sent to a laboratory. The lab exposes your blood cells to synthetic proteins that mimic parts of the TB bacterium and then measures whether your immune cells release interferon-gamma in response. A significant release indicates your immune system has encountered TB before.
Results typically come back in one to three days, depending on the lab. You do not need a return visit for someone to read a physical reaction. The result comes back as positive, negative, or indeterminate. An indeterminate result means the test could not produce a reliable answer, often because the control sample did not behave as expected, and you may need to retest.
When the Blood Test Is the Better Choice
Clinical guidelines from the American Thoracic Society, CDC, and Infectious Diseases Society of America recommend using an IGRA rather than a skin test in two specific scenarios: when the person has been vaccinated with BCG, and when the person is unlikely to return for the 48-to-72-hour skin test reading.3American Journal of Respiratory and Critical Care Medicine. Official Clinical Practice Guidelines of the American Thoracic Society, Centers for Disease Control and Prevention, and Infectious Diseases Society of America: Diagnosis of Tuberculosis in Adults and Children – Section: Testing for LTBI The BCG issue is significant because this vaccine is given routinely in much of the world, and it can cause the skin test to come back positive even when the person does not have TB infection.
The numbers back this up. One study found that BCG-vaccinated individuals were nearly five times more likely to have a positive skin test reaction compared to unvaccinated individuals, even after accounting for actual TB exposure. The blood test was not thrown off by BCG vaccination.4European Respiratory Journal. Avoiding the effect of BCG vaccination in detecting Mycobacterium tuberculosis infection with a blood test Research in HIV-positive patients from a low-prevalence country confirmed the same pattern: about a third of BCG-vaccinated individuals had positive skin tests compared to roughly 11% of unvaccinated individuals, while IGRAs were unaffected by vaccination history.5PubMed. Tuberculosis skin test, but not interferon-γ-releasing assays is affected by BCG vaccination in HIV patients
Beyond BCG, the blood test also avoids another skin test limitation: false positives from exposure to environmental mycobacteria, which are non-TB bacteria found in soil and water. The IGRA uses proteins specific to the TB bacterium that these environmental organisms do not share, so the signal is cleaner.6PubMed Central. Comparison of a new ESAT-6/CFP-10 peptide-based gamma interferon assay and a tuberculin skin test for tuberculosis screening in a moderate-risk population
That said, a skin test remains an acceptable alternative in almost all situations, and the CDC guidelines say so explicitly. In settings where IGRA testing is unavailable, too expensive, or logistically difficult, the skin test is still a reasonable option.7Morbidity and Mortality Weekly Report. Updated Guidelines for Using Interferon Gamma Release Assays to Detect Mycobacterium tuberculosis Infection — United States, 2010 – Section: Recommendations
Testing Children
For children younger than five, guidelines lean toward the skin test as the first choice. The concern with blood tests in very young children is not safety but sensitivity: there has been limited data on how reliably IGRAs detect infection in this age group, and experts have worried that young children’s immune responses might not produce enough interferon-gamma to register.3American Journal of Respiratory and Critical Care Medicine. Official Clinical Practice Guidelines of the American Thoracic Society, Centers for Disease Control and Prevention, and Infectious Diseases Society of America: Diagnosis of Tuberculosis in Adults and Children – Section: Testing for LTBI
That preference is starting to soften, though. A review of data from high-risk children under two years old found that none of 575 untreated children with negative IGRA results went on to develop TB disease, including 70 who had been skin-test positive but blood-test negative.8PubMed. Use of Interferon-Gamma Release Assays in Children <2 Years Old The American Academy of Pediatrics now acknowledges that IGRAs are an acceptable alternative in young children, particularly BCG-vaccinated kids where specificity matters most.9Pediatrics. Tuberculosis Infection in Children and Adolescents: Testing and Treatment – Section: Strategies for the Use of IGRAs in Children One important caveat: in infants younger than three months, neither test is considered reliable for ruling out infection, because the immune system is too immature to mount a measurable response.
The bottom line for parents: only test your child if there is a genuine risk factor, such as close contact with someone who has active TB, recent travel to a high-burden country, or a household member who was recently diagnosed. Routine screening of low-risk children is not recommended.
Testing During Pregnancy
Both the skin test and the blood test are considered safe during pregnancy. Neither poses a risk to the fetus. The question is which one performs better. Research among HIV-positive pregnant women in a high-burden setting found that the blood test detected latent TB infection in a substantially higher proportion of women than the skin test: about 35% tested positive on the IGRA versus roughly 14% on the TST. The most common pattern of disagreement was a positive blood test paired with a negative skin test, suggesting pregnancy may blunt the skin reaction more than it affects the blood-based immune response.10PubMed Central. Effect of pregnancy on interferon gamma release-assay and tuberculin skin test detection of latent TB infection among HIV-infected women in a high burden setting – Section: Results
If you are pregnant and your provider recommends TB testing, ask whether a blood test is available. It appears to be the more sensitive option during pregnancy, though either test can be used.
What a Positive Result Actually Means
A positive TB test does not mean you have active tuberculosis. It means your immune system has encountered the TB bacterium at some point. Most people with a positive result have what is called latent TB infection: the bacteria are present in the body but kept in check by the immune system. There are no symptoms, no ability to spread the disease to others, and no abnormalities on a chest X-ray.11PubMed Central. Tuberculosis Infection and Latent Tuberculosis Latent infection is defined by a persistent immune response to TB proteins without any clinical evidence of disease.12PubMed Central. Latent tuberculosis infection: An overview
Active TB, by contrast, involves a much higher burden of bacteria and comes with symptoms: a persistent cough lasting three weeks or more, fever, night sweats, weight loss, and sometimes coughing up blood. Active TB is contagious. If your screening test comes back positive, the next step is always a chest X-ray and possibly sputum tests to determine whether the infection is latent or active. This is not optional; it is the standard follow-up.
Factors That Can Produce Misleading Results
Neither test is perfect, and several things can push results in the wrong direction. For the skin test specifically:
- BCG vaccination: as discussed above, can cause false-positive reactions on skin testing but does not affect blood tests.
- Malnutrition: people with significant protein malnutrition are less likely to mount a measurable skin reaction, even if they are infected. Research in Peru found that lower body protein was associated with false-negative skin test results.13PubMed Central. Tuberculosis skin testing, anergy and protein malnutrition in Peru
- Immunosuppression: conditions like HIV or medications that suppress the immune system can blunt the response to either test, leading to false negatives. Disseminated TB disease itself can paradoxically cause false-negative results on immune-based tests because the overwhelming infection suppresses the very immune response the test tries to measure.14PLOS ONE. Accuracy of Immunodiagnostic Tests for Active Tuberculosis Using Single and Combined Results: A Multicenter TBNET-Study – Section: Discussion
- Reader error: the skin test depends on a trained person feeling for induration and measuring it accurately. Inexperienced readers sometimes measure redness instead of hardness, or round their measurements inconsistently.
For blood tests, the main issue is indeterminate results. These happen more often in people with weakened immune systems, because the positive control in the test tube may not respond properly. An indeterminate result is not a negative; it just means the lab could not produce a trustworthy answer from that sample.
Two-Step Testing for Workplace Screening
If you are starting a new healthcare job, you may encounter something called two-step skin testing. This is not about doing two different types of tests. It means getting a second skin test one to three weeks after the first one, even if the first was negative. The reason is a phenomenon called boosting: in someone who was exposed to TB years ago but whose immune memory has faded, the first test can “wake up” the immune response without producing a visible reaction. The second test then picks up the now-primed response.
A study at a New York City hospital found this to be surprisingly common. Of 155 new employees who tested negative on their initial skin test, about 10% converted to positive on the second test administered a week later. Without two-step testing, those individuals would have been incorrectly classified as newly infected when they later tested positive on routine annual screening, inflating the hospital’s apparent conversion rate by nearly 50%.15PubMed Central. Benefit of two-step PPD testing of new employees at a New York City hospital – Section: RESULTS If your employer requires two-step testing, this is why. It establishes your true baseline so that future tests can meaningfully detect new exposure.
What Happens If You Need Treatment
If testing reveals latent TB infection, your provider will likely recommend preventive treatment to reduce the risk of the infection becoming active disease. Several regimens exist. The traditional course was nine months of daily isoniazid, which works but has a high dropout rate because of the duration. Shorter options have become available, including a 3-month once-weekly combination of isoniazid and rifapentine, often called the 3HP regimen, which the WHO now recommends and which is being rolled out in countries including India.16PubMed Central. The 3 HP regimen for tuberculosis preventive treatment: safety, dosage and related concerns during its large-scale implementation in countries like India The shorter regimen makes completion much more realistic for most people.
Active TB disease requires a longer, multi-drug treatment course, typically four drugs for the first two months followed by two drugs for an additional four months. This is not something you manage on your own. Active TB treatment involves directly observed therapy in many settings, meaning a healthcare worker watches you take your medication to ensure the full course is completed. Incomplete treatment breeds drug-resistant strains, which is why public health systems take completion so seriously.
Cost and Access Barriers
In the United States, the cost of a TB skin test at a public health department is often free or under $25. Blood tests typically cost more, ranging from $50 to over $200 depending on the lab and whether you have insurance. Many local health departments offer free TB testing regardless of insurance status, particularly for people who are at higher risk. Pharmacies and urgent care clinics tend to charge more but offer convenience.
Globally, cost and access look very different. Even in countries with free TB diagnostic services, patients often face substantial out-of-pocket expenses from transportation, lost wages, and repeat visits. Research in Kenya found that TB patients faced an average of roughly $56 in direct costs and nearly $300 in indirect costs from lost income, creating what the authors called a “medical poverty trap” where spending rose while earnings fell.17PubMed Central. Assessing access barriers to tuberculosis care with the tool to Estimate Patients’ Costs: pilot results from two districts in Kenya – Section: RESULTS Similarly, research in Indonesia found that patients without health insurance paid significantly more in pretreatment costs, and those who visited multiple providers before receiving a diagnosis accumulated the highest expenses.18PubMed Central. Out-of-Pocket Costs for Patients Diagnosed with Tuberculosis in Different Healthcare Settings in Bandung, Indonesia
Geographic access is another challenge. In parts of sub-Saharan Africa, the majority of the population lives more than 10 kilometers from a facility that can perform TB testing, and some entire districts lack any facility providing the service.19PubMed Central. Geographic accessibility to public health facilities providing tuberculosis testing services at point-of-care in the upper east region, Ghana – Section: Results This is one reason point-of-care diagnostics have received so much attention in recent years.
Point-of-Care and Emerging Diagnostics
The traditional lab-dependent model of TB testing has obvious limitations in resource-limited settings. Newer point-of-care platforms aim to bring reliable TB diagnosis closer to the patient. One example is the Truenat system, a portable molecular test that can detect TB and rifampicin resistance from a sputum sample. A cost-effectiveness analysis modeled for India’s public sector found that deploying Truenat at the point of care increased life expectancy by about 0.39 years compared to traditional sputum smear microscopy and correctly detected substantially more TB cases per 10,000 people tested.20PubMed Central. Rapid, point-of-care diagnosis of tuberculosis with novel Truenat assay: Cost-effectiveness analysis for India’s public sector – Section: Base case clinical outcomes
These molecular tests differ from the skin test and blood test in an important way: they detect active TB disease by finding the bacterium’s genetic material in sputum, rather than detecting the immune response to past exposure. They do not replace the TST or IGRA for latent infection screening. Instead, they fill a different gap, catching active cases faster so treatment can begin before the disease spreads. For readers in higher-income countries, the GeneXpert system serves a similar role and is increasingly available in hospital laboratories and reference labs, though it is not yet a routine screening tool for latent infection.
Research into new skin tests is also underway. Several candidates use the same TB-specific proteins found in IGRAs but deliver them as a skin injection rather than a blood draw, potentially combining the simplicity and low cost of a skin test with the specificity of a blood test. These newer skin tests have shown promising results in trials, though none have yet achieved widespread clinical adoption outside of research settings.